EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
FEB 2025
-
EDITION 19
-
TABLES 108
-
REGIONS 13
-
SEGMENTS 10
-
PAGES 573
-
US$ 5600
-
MCP-1392
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
QUESTIONNAIRE
EXECUTIVES
DATA ROOM
HIGHLIGHTS & REPORT INDEX
Global Genetic Testing Market to Reach US$26.4 Billion by 2030
The global market for Genetic Testing estimated at US$13.7 Billion in the year 2023, is expected to reach US$26.4 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2023-2030. Prenatal & Newborn, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$8.9 Billion by the end of the analysis period. Growth in the Diagnostic segment is estimated at 9.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 11.9% CAGR
The Genetic Testing market in the U.S. is estimated at US$5.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 9.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.
Global Genetic Testing Market - Key Trends & Drivers Summarized
What Is Genetic Testing and How Does It Impact Healthcare?
Genetic testing involves analyzing DNA sequences to identify changes in genes, chromosomes, or proteins that could indicate the presence of or risk for developing genetic disorders. This type of testing has revolutionized the medical field by enabling early diagnosis and personalized treatment plans for a wide array of diseases, including cancers, cardiovascular diseases, and rare genetic disorders. By identifying specific genetic mutations, healthcare providers can tailor treatments to individual patients, enhancing treatment efficacy and potentially reducing side effects. Genetic testing also plays a pivotal role in prenatal screening, carrier screening, and in predicting an individual’s risk of developing certain diseases.
What Technological Advancements Are Shaping Genetic Testing?
The field of genetic testing has been profoundly impacted by advancements in genomic technologies, particularly next-generation sequencing (NGS) and CRISPR. NGS allows for the rapid sequencing of entire genomes at a fraction of the cost and time previously required. This technology has not only expanded the accessibility of genetic testing but also improved the accuracy and reliability of the results. Meanwhile, CRISPR technology, known for its gene-editing capabilities, is being explored for its potential to correct genetic defects before they can lead to disease. Additionally, improvements in bioinformatics and the integration of artificial intelligence have enhanced the ability to analyze and interpret large sets of genetic data, providing more detailed and actionable insights.
How Are Regulatory and Ethical Considerations Influencing the Genetic Testing Market?
The genetic testing market is heavily influenced by regulatory and ethical considerations. As genetic testing becomes more commonplace, issues such as privacy, consent, and access to genetic information have prompted governments worldwide to establish strict guidelines and regulations. These regulations aim to protect individuals from genetic discrimination and ensure that genetic data is handled with confidentiality and integrity. Furthermore, ethical concerns regarding how genetic testing is used—for example, in prenatal screening or for determining the likelihood of developing late-onset diseases—continue to shape public policy and influence consumer acceptance and trust in genetic testing services.
What Drives the Growth in the Genetic Testing Market?
The growth in the genetic testing market is driven by several factors, including the increasing prevalence of genetic disorders, technological advancements in genetics, and a growing awareness of the benefits of early disease detection and prevention. The expansion of direct-to-consumer genetic testing kits has also significantly contributed to market growth, as more individuals take proactive steps towards understanding their genetic health. Additionally, healthcare systems are increasingly adopting personalized medicine practices, which rely heavily on genetic insights to craft individualized treatment plans. Moreover, ongoing research and development activities, supported by funding from governments and private entities, are continually uncovering new applications for genetic testing, further broadening the market`s scope.
SCOPE OF STUDY
The report analyzes the Genetic Testing market by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic, Other Types); Application (Cancer, Genetic Disease, Cardiovascular Disease, Other Applications).
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World..
SELECT PLAYERS
Agilent Technologies, Inc.; Asuragen, Inc.; Biocartis NV; Agena Bioscience, Inc.; ARUP Laboratories; Bioiberica SAU; AutoGenomics, Inc.; Biodesix, Inc.; Admera Health; Annoroad Gene Technology; Berry Genomics Co., Ltd.; Ariel Precision Medicine, Inc.; AlphaBiolabs Ltd. ; AnchorDx; Alexian Brothers of America, Inc.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Genetic Testing – Global Key Competitors Percentage Market Share in 2024 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 249 Players Worldwide in 2024 (E) |
| A Prelude to Genetic Testing |
| Top Ten Genetic Diseases Worldwide |
| Different Types of Genetic Tests include |
| Prenatal and Newborn Screening |
| Diagnostic Testing |
| Predictive & Presymptomatic Testing |
| Carrier Identification |
| Pharmacogenomic Testing |
| List of Genetic Disorders by Event, Genetic Manifestation and Prevalence |
| Genetic Testing Delivery Models |
| Genetic Sequencing Approaches |
| Expanding Applications to Drive Genetic Testing Market |
| Regional Landscape |
| Prenatal Testing Market to Rise |
| Market Outlook |
| 2. FOCUS ON SELECT PLAYERS |
| Recent Market Activity |
| World Brands |
| Innovations |
| 3. MARKET TRENDS & DRIVERS |
| SEGMENT ANALYSIS |
| Prenatal Testing – Changing the World of Pregnancy Care |
| List of Available Prenatal Screening and Diagnostic Tests by Indication |
| Players in the Prenatal and New Born Genetic Testing Market |
| Conventional Invasive Pre-Natal Diagnostic Techniques – A Risky Affair |
| Emergence of Non-Invasive Prenatal Diagnosis (NIPD) |
| Competition Intensifies in the NIPD Market |
| Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing |
| Predictive Diagnostics |
| Breast Cancer Gene Testing Market to Expand Strongly |
| Myriad Genetics – A Leader in Breast Cancer Testing |
| Discovery of Novel Biomarkers Crucial to Predictive Diagnostics |
| Pharmacogenomics Development Augurs Growth of Genetic Testing Market |
| MARKET TRENDS AND GROWTH DRIVERS |
| Genetic Testing Paves the Way for Personalized Medicine |
| TABLE 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medic |
| Next-Generation Sequencing (NGS) – A Giant Leap in Genome Sequencing |
| Biomarker Discovery Leads to Advanced Genetic Testing |
| Select List of Available Tumor Markers |
| Immense Popularity of Ancestry Testing |
| Increasing Focus on Data Churning |
| Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases |
| Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing |
| Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment |
| Hybrid Labs to Bridge Gap Between Traditional and DTC Models |
| Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing |
| Emergence of Rapid DNA Testing |
| Oncology – A Key Focus Area for Genetic Testing |
| EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 |
| Ageing Demographics to Drive Demand for Genetic Testing |
| EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Genetic Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
| Use of Genomic Data in Clinical Settings to Gather Pace |
| The United States: Leading Market for Genetic Testing Globally |
| Predictive Screening: Another Growth Area |
| Growing Relevance of Personalized Medicine Augurs Well |
| Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing |
| Newborn Testing Gains Ground |
| Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing |
| Coverage of NIPT in Average Risk Pregnancies Expands Target Market |
| Direct-to-Consumer Testing: A Growing Market |
| Favorable Reimbursement Policies |
| Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing |
| Demographic Changes Offer Growth Opportunities |
| TABLE 14: North American Aging Population by Age Group: 1975-2050 |
| Skepticism Limits Widespread Adoption of Genetic Testing |
| Competitive Overview |
| Myriad Eyes Diversification and Expansion for Growth |
| Natera Holds Fort in the NIPT Market |
| Invitae Banks on Low Cost Solutions for Expanding Revenues |
| Regulatory Environment |
| Genetic Information Nondiscrimination Act Boosts Genetic Testing |
| Stricter Regulations for DTC Genetic Testing |
| FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests |
| Select Genetic Test Reimbursement Codes |
| Market Analytics |
| USA Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| USA 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| USA Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| USA Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| USA 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| CANADA |
| Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand |
| Regulatory Scenario |
| Market Analytics |
| Canada Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Canada 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Canada Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Canada Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Canada 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| JAPAN |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
| Demographics Drive Market Growth |
| DTC Genetic Testing Regulatory Scenario |
| Japan Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Japan 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Japan Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Japan Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Japan 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| CHINA |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
| Market Overview |
| China Attracts Domestic and Foreign Players |
| Strong Focus on Genomics |
| Genetic Testing to Reveal Real Talent in Children – A New Popular Application |
| China to Take Lead in Rapidly Growing Asian Genomics Market |
| Market Analytics |
| China Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| China 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| China Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| China Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| China 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| EUROPE |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
| European Personalized Medicine Market to Exhibit Robust Growth |
| Aging Population to Drive Demand for Genetic Testing |
| TABLE 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above |
| Legislations/Regulatory Policies in Select European Countries |
| Legislations Governing Genetic Testing in Select European Countries |
| Rising Cancer Incidence Augurs Well for European Genetic Testing Market |
| Europe Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Europe 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030 |
| Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Europe 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Europe 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| FRANCE |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
| France Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| France 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| France Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| France Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| France 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| GERMANY |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
| Parliamentary Regulations |
| Germany Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Germany 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Germany Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Germany Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Germany 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Italy 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Italy Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Italy Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Italy 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| UNITED KINGDOM |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
| Increased Support for Personalized Medicine to Drive Genetic Testing |
| SMIP for Pharmacogenomic Testing |
| Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK |
| Principles for DTC Genetic Testing Laid out by HGC |
| UK Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| UK 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| UK Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| UK Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| UK 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of Europe 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of Europe 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| ASIA-PACIFIC |
| Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
| Healthcare Spending in Asia-Pacific: On the Rise |
| India |
| Australia and New Zealand |
| Market Analytics |
| Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Asia-Pacific 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Asia-Pacific 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| REST OF WORLD |
| Predictive Screening: Another Growth Area |
| Market Analytics |
| Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of World 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2024 & 2030 |
| Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of World Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of World 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2024 & 2030 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com